ibrutinib + lenalidomide + DA-EPOCH-R

This is a **combination regimen** comprised of three main components: **ibrutinib**, **lenalidomide**, and **DA-EPOCH-R**. - **Ibrutinib** is a small molecule inhibitor that binds covalently to Bruton's tyrosine kinase, a critical enzyme in B-cell receptor signaling, resulting in inhibition of malignant B-cell proliferation and survival. - **Lenalidomide** is an immunomodulatory agent that has direct anti-tumor effects, inhibits angiogenesis, and modulates the immune system to enhance immune-mediated tumor destruction. - **DA-EPOCH-R** (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab) is an intensive chemotherapy regimen designed for aggressive B-cell lymphomas, including MYC-rearranged lymphomas and "double-hit" or "triple-hit" lymphomas. DA-EPOCH-R combines a monoclonal antibody (rituximab) and multiple cytotoxic agents with different mechanisms: anthracycline (doxorubicin), alkylating agent (cyclophosphamide), topoisomerase inhibitor (etoposide), vinca alkaloid (vincristine), and corticosteroid (prednisone)[1][2][3][4][5]. This regimen is used primarily in high-risk or refractory lymphoma, with the intention of maximizing anti-tumor activity by targeting complementary oncogenic pathways.

Other names

DA-EPOCH-R-Pharmacyclics LLC.-diffuse large B-cell lymphomaIbrutinib and Lenalidomide with DA-EPOCH-RDA-EPOCH-R plus ibrutinib and lenalidomide